Nanocarriers for targeted drug delivery

Benefits and challenges of nanotechnology for medicine

Russell Maguire

ENGI4131 Advanced Semiconductor Devices

Durham University

November 28, 2018






Nanocarrier delivery systems

Introduction





micelle liposome polymeric *peg*ylated drug micelle liposome conjugate











Figure 1: Structure of common types of nanocarriers.

Definition: nanocarrier

Biocompatible nanoparticle encapsulating a drug

Characteristics

- Nanometer scale
 - Biodegradable Hydrophilic
- blodegradable
- Soluble

Low toxicity

 Not immunogenic

Soluble





How is targeted drug delivery effective?

diseased tissue healthy tissue

general drug

Introduction





targeted drug





Figure 2: Goal is to increase drug concentration ratio for diseased tissue.

Targets diseased tissue

- Maximise therapeutic effects
- Minimise effective drug dose
- Common targets are solid tumours, inflamed and infected tissue

Avoids healthy tissue

Minimise toxic side-effects





am

Vascular permeability

Passive targeting

Definition: vascular permeability

 Tendency for molecules to leak from blood vessels into interstitial space between cells

Contributing factors

- Permeability enhancers such as bradykinin and nitric oxide
- Dense and defective blood vessels
- Enhanced vascular permeability has been observed in solid tumours and inflamed tissue [1]



Enhanced permeability and retention effect

Passive targeting

Basis for first generation nanomedicines [2]

Definition: EPR effect

 Tendency for nanoparticles to accumulate in solid tumours [1]

Accumulation procedure

- Molecules leak into interstitial space due to enhanced vascular permeability
- 2 Lymphatic vessels are compressed by rapidly growing solid tumour [3]
- 3 Large particles become trapped



^[1] H. Maeda et al., Journal of controlled release 65, 271–284 (2000).

^[2] A. Wicki et al., Journal of controlled release 200, 138-157 (2015).

^[3] T. P. Padera et al., Nature 427, 695 (2004).

Internal stimuli-responsive nanocarriers

Stimuli-responsive targeting

Bioindicators used to trigger release

- Tumours have been observed with lower pH than healthy tissue [4, 5]
- Individual organelles maintain their own unique pH and redox potential
- Intracellular and extracellular space maintain different redox potentials [6]





^[4] I. F. Tannock, D. Rotin, Cancer research 49, 4373-4384 (1989).

^[5] L. E. Gerweck, K. Seetharaman, Cancer research 56, 1194–1198 (1996).

^[6] G. Saito et al., Advanced drug delivery reviews 55, 199-215 (2003).

External stimuli-responsive nanocarriers

Stimuli-responsive targeting

Mechanisms used to externally trigger release

- Electromagnetic fields
- Heat

Ultrasound

Light





Surface ligands

Active targeting

Definition: active targeting







Thank you, any questions?

References

- 1. H. Maeda et al., Journal of controlled release 65, 271-284 (2000).
- 2. A. Wicki et al., Journal of controlled release 200, 138-157 (2015).
- 3. T. P. Padera et al., Nature 427, 695 (2004).
- 4. I. F. Tannock, D. Rotin, Cancer research 49, 4373-4384 (1989).
- L. E. Gerweck, K. Seetharaman, Cancer research 56, 1194–1198 (1996).
- 6. G. Saito et al., Advanced drug delivery reviews 55, 199–215 (2003).



